LOS ANGELES, CA, USA I October 30, 2014 I ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
According to Mayo Clinic, Staph bacteria are normally found on the skin or in the nose of about one-third of the population. The bacteria are generally harmless unless they enter the body through a cut or other wound, and even then they usually cause only minor skin problems in healthy people. MRSA infection is caused by a strain of staph bacteria that’s become resistant to the antibiotics commonly used to treat ordinary staph infections. This can allow the infections to spread and sometimes become life-threatening. According to the CDC MRSA kills about 11,000 people each year in the United States.
ViaDerma’s founder and CEO Dr. Christopher Otiko comments, “Initial case studies involving TetraStem have showed remarkable success. The most memorable was a woman in Florida who was on IV antibiotics for Systemic MRSA. The patient’s MRSA infection was drug resistant and the usual medications were not working. However, after advising the patient to apply TetraStem directly to her neck and wrist the patient was symptom-free within two months.”
ViaDerma is currently in negotiations to test TetraStem at hospitals in Florida with plans to expand the use of the drug across America. TetraStem is currently being sold in various retail outlets. For more information about TetraStem, please visit www.viadermalicensing.com.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
SOURCE: ViaDerma
Post Views: 82
LOS ANGELES, CA, USA I October 30, 2014 I ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
According to Mayo Clinic, Staph bacteria are normally found on the skin or in the nose of about one-third of the population. The bacteria are generally harmless unless they enter the body through a cut or other wound, and even then they usually cause only minor skin problems in healthy people. MRSA infection is caused by a strain of staph bacteria that’s become resistant to the antibiotics commonly used to treat ordinary staph infections. This can allow the infections to spread and sometimes become life-threatening. According to the CDC MRSA kills about 11,000 people each year in the United States.
ViaDerma’s founder and CEO Dr. Christopher Otiko comments, “Initial case studies involving TetraStem have showed remarkable success. The most memorable was a woman in Florida who was on IV antibiotics for Systemic MRSA. The patient’s MRSA infection was drug resistant and the usual medications were not working. However, after advising the patient to apply TetraStem directly to her neck and wrist the patient was symptom-free within two months.”
ViaDerma is currently in negotiations to test TetraStem at hospitals in Florida with plans to expand the use of the drug across America. TetraStem is currently being sold in various retail outlets. For more information about TetraStem, please visit www.viadermalicensing.com.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
SOURCE: ViaDerma
Post Views: 82
